Despite mammalian cell cultures being the preferred manufacturing approach for biologics, recent advances in microbial fermentation have enabled the development of versatile biomanufacturing systems, which are both robust and cost friendly. Presently, a number of service provider companies claim to offer end-to-end solutions, ranging from product development to commercial production, for microbial biologics. Given the obvious advantages of outsourcing, drug developers are likely to continue relying on contract service providers for various aspects of their respective microbial biologic development programs.

 

To order this 320+ page report, which features 150+ figures and 150+ tables, please visit this link

 

The USD 9.3 billion (by 2030) financial opportunity within the microbial biomanufacturing market has been analyzed across the following segments:

• Type of Product
• API
• FDF

 

• Type of Biologic

• Proteins
• Enzymes
• Growth Hormones
• Antibody based Drugs
• Others (plasmid DNA, probiotics, microbiome-based biologics)

 

• Type of Microbial Expression System

• Bacteria
• Yeast
• Others (Algae and fungi)

 

• Scale of Operation
• Commercial
• Preclinical / Clinical

 

• Type of End User
• Small Companies
• Mid-sized Companies
• Large / Very Large Companies

 

• Key Geographical Regions
• North America
• Europe
• Asia Pacific
• Middle East and North Africa
• Latin America

 

The Microbial Contract Biomanufacturing Market, 2020-2030 report features the following companies, which we identified to be key players in this domain:

• AGC Biologics
• Aldevron
• BioVectra
• EirGenix
• Etinpro
• Eurogentec
• Northway Biotechpharma
• Ology Bioservices
• Porton Biopharma
• Stelis Biopharma

 

Table of Contents

 

1. Preface

2. Executive Summary

3. Introduction
 

4. Market Landscape
 

5. Company Competitiveness Analysis

 

6. Company Profiles
 

7.  Recent Partnerships
 

8.  Recent Expansions
 

9.  Microbial fermentation technology platforms
 

10. Assessment of Relative Competition and Growth
 

11. Make versus Buy Decision Making Framework

 

12.  Big Pharma Initiatives in Microbial Biomanufacturing

 

13. Case study: comparison of small molecule and large

 

14. Market Sizing and Opportunity Analysis
 

15. Impact of covid-19 pandemic on microbial contract biomanufacturing market

 

16. Swot Analysis

 

17. Conclusion Appendix 3: List of Companies and Organizations

18. Interview Transcripts

 

19. Appendix 1: Tabulated Data

 

20. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com